452 related articles for article (PubMed ID: 16780568)
1. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
3. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
4. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Mulhall JP; Montorsi F
Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
7. Emerging oral drugs for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
[TBL] [Abstract][Full Text] [Related]
8. [Tadalafil and patients preference in the treatment of erectile dysfunction].
Hu JL; Chen B
Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1145-8. PubMed ID: 17201266
[TBL] [Abstract][Full Text] [Related]
9. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
12. Treatment of erectile dysfunction.
Dinsmore W
Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Berner MM; Kriston L; Harms A
Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
[TBL] [Abstract][Full Text] [Related]
14. [Update of PDE5 inhibitors as treatment of ED].
Lu YN; Chen B
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
[TBL] [Abstract][Full Text] [Related]
15. [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval].
Giuliano F; Vicaut E; Jeanpetit Y
Prog Urol; 2008 Sep; 18(8):536-42. PubMed ID: 18760744
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of phosphodiesterase 5 inhibitors.
Carrier S
Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845
[TBL] [Abstract][Full Text] [Related]
17. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
[TBL] [Abstract][Full Text] [Related]
19. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
Zhang SX; Gao P
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction].
Jin J; Guo Y
Zhonghua Nan Ke Xue; 2004 Sep; 10(9):711-6. PubMed ID: 15497717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
